- Home
- RMCO vs CLDI Comparison
RMCO vs CLDI Comparison
Compare RMCO & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMCO
- CLDI
- Stock Information
- Founded
- RMCO 2021
- CLDI 2014
- Country
- RMCO United States
- CLDI United States
- Employees
- RMCO N/A
- CLDI N/A
- Industry
- RMCO Multi-Sector Companies
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RMCO Miscellaneous
- CLDI Health Care
- Exchange
- RMCO Nasdaq
- CLDI Nasdaq
- Market Cap
- RMCO 14.9M
- CLDI 14.0M
- IPO Year
- RMCO N/A
- CLDI N/A
- Fundamental
- Price
- RMCO $1.22
- CLDI $0.48
- Analyst Decision
- RMCO
- CLDI Strong Buy
- Analyst Count
- RMCO 0
- CLDI 2
- Target Price
- RMCO N/A
- CLDI $15.00
- AVG Volume (30 Days)
- RMCO 46.5K
- CLDI 386.9K
- Earning Date
- RMCO 05-23-2025
- CLDI 05-13-2025
- Dividend Yield
- RMCO N/A
- CLDI N/A
- EPS Growth
- RMCO N/A
- CLDI N/A
- EPS
- RMCO N/A
- CLDI N/A
- Revenue
- RMCO $807,089.00
- CLDI N/A
- Revenue This Year
- RMCO N/A
- CLDI N/A
- Revenue Next Year
- RMCO N/A
- CLDI N/A
- P/E Ratio
- RMCO N/A
- CLDI N/A
- Revenue Growth
- RMCO 65.21
- CLDI N/A
- 52 Week Low
- RMCO $0.70
- CLDI $0.35
- 52 Week High
- RMCO $1.59
- CLDI $4.90
- Technical
- Relative Strength Index (RSI)
- RMCO 65.32
- CLDI 38.44
- Support Level
- RMCO $1.12
- CLDI $0.41
- Resistance Level
- RMCO $1.28
- CLDI $0.45
- Average True Range (ATR)
- RMCO 0.10
- CLDI 0.07
- MACD
- RMCO 0.02
- CLDI 0.02
- Stochastic Oscillator
- RMCO 83.56
- CLDI 56.57
About RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.